CN1845999A - 在卵巢癌中作为预后和治疗靶标而被调控的基因 - Google Patents
在卵巢癌中作为预后和治疗靶标而被调控的基因 Download PDFInfo
- Publication number
- CN1845999A CN1845999A CNA2004800250336A CN200480025033A CN1845999A CN 1845999 A CN1845999 A CN 1845999A CN A2004800250336 A CNA2004800250336 A CN A2004800250336A CN 200480025033 A CN200480025033 A CN 200480025033A CN 1845999 A CN1845999 A CN 1845999A
- Authority
- CN
- China
- Prior art keywords
- gene
- expression
- ovarian cancer
- sample
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48446503P | 2003-07-02 | 2003-07-02 | |
US60/484,465 | 2003-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1845999A true CN1845999A (zh) | 2006-10-11 |
Family
ID=34062046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004800250336A Pending CN1845999A (zh) | 2003-07-02 | 2004-07-01 | 在卵巢癌中作为预后和治疗靶标而被调控的基因 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1644522A2 (ja) |
JP (1) | JP2007526749A (ja) |
CN (1) | CN1845999A (ja) |
AU (1) | AU2004256182A1 (ja) |
BR (1) | BRPI0412110A (ja) |
CA (1) | CA2531091A1 (ja) |
MX (1) | MXPA05014220A (ja) |
WO (1) | WO2005005661A2 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106841622A (zh) * | 2017-04-07 | 2017-06-13 | 南通大学附属医院 | Scml2在诊断胃肠胰神经内分泌肿瘤中的应用 |
CN107385068A (zh) * | 2010-08-27 | 2017-11-24 | 明斯特大学临床医学院 | 用于检测女性受试者患复发性流产、先兆子痫和/或胎儿生长受限的倾向的工具和方法 |
CN108085392A (zh) * | 2018-01-09 | 2018-05-29 | 山大生殖研发中心有限公司 | 上皮性卵巢癌的生物标志物及其用途 |
CN110241198A (zh) * | 2019-05-30 | 2019-09-17 | 成都吉诺迈尔生物科技有限公司 | 一种表征hHRD同源重组缺陷的基因组重组指纹及其鉴定方法 |
CN112229999A (zh) * | 2020-09-01 | 2021-01-15 | 浙江省肿瘤医院 | 一种卵巢癌的预后诊断标志物Claudin21及其应用 |
CN113684277A (zh) * | 2021-09-06 | 2021-11-23 | 南方医科大学南方医院 | 一种基于基因组拷贝数变异的生物标志物预测卵巢癌同源重组缺陷的方法及应用 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1899482A2 (en) * | 2005-04-07 | 2008-03-19 | Novartis Vaccines and Diagnostics, Inc. | Ddr2 in cancer diagnosis, detection and treatment |
EP1806413A1 (en) * | 2006-01-06 | 2007-07-11 | Oligene GmbH | An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer |
AU2007321070B2 (en) * | 2006-11-13 | 2013-11-21 | Valipharma | Methods and uses involving genetic abnormalities at chromosome 12 |
GB0815846D0 (en) * | 2008-09-01 | 2008-10-08 | Immunovia Ab | diagnosis, prognosis and imaging of disease |
WO2011085263A2 (en) | 2010-01-11 | 2011-07-14 | Genomic Health, Inc. | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
ES2829415T3 (es) | 2013-05-30 | 2021-05-31 | Genomic Health Inc | Algoritmo de perfil de expresión génica para calcular una puntuación de recurrencia para un paciente con cáncer de riñón |
CN103920150B (zh) * | 2014-04-17 | 2016-02-03 | 北京大学第一医院 | Satb1在治疗皮肤t细胞淋巴瘤中的应用 |
JP6436477B2 (ja) * | 2014-05-13 | 2018-12-12 | 国立大学法人大阪大学 | 癌治療用医薬組成物 |
JP6168625B2 (ja) * | 2016-01-12 | 2017-07-26 | 国立研究開発法人産業技術総合研究所 | 上皮性卵巣癌鑑別マーカー |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001018542A2 (en) * | 1999-09-03 | 2001-03-15 | Millennium Pharmaceuticals, Inc. | Identification, assessment, prevention, and therapy of ovarian cancer |
AU4592601A (en) * | 2000-03-21 | 2001-10-03 | Millennium Predictive Medicine | Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer |
US20030003479A1 (en) * | 2001-04-19 | 2003-01-02 | Millennium Pharmaceutical, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
AU2002324881A1 (en) * | 2001-09-05 | 2003-03-18 | Wesleyan University | Diagnostic and prognostic tests |
-
2004
- 2004-07-01 BR BRPI0412110-4A patent/BRPI0412110A/pt not_active Application Discontinuation
- 2004-07-01 AU AU2004256182A patent/AU2004256182A1/en not_active Abandoned
- 2004-07-01 CN CNA2004800250336A patent/CN1845999A/zh active Pending
- 2004-07-01 MX MXPA05014220A patent/MXPA05014220A/es not_active Application Discontinuation
- 2004-07-01 WO PCT/EP2004/007167 patent/WO2005005661A2/en not_active Application Discontinuation
- 2004-07-01 JP JP2006518084A patent/JP2007526749A/ja active Pending
- 2004-07-01 CA CA002531091A patent/CA2531091A1/en not_active Abandoned
- 2004-07-01 EP EP04740533A patent/EP1644522A2/en not_active Withdrawn
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107385068A (zh) * | 2010-08-27 | 2017-11-24 | 明斯特大学临床医学院 | 用于检测女性受试者患复发性流产、先兆子痫和/或胎儿生长受限的倾向的工具和方法 |
CN106841622A (zh) * | 2017-04-07 | 2017-06-13 | 南通大学附属医院 | Scml2在诊断胃肠胰神经内分泌肿瘤中的应用 |
CN106841622B (zh) * | 2017-04-07 | 2019-01-18 | 南通大学附属医院 | Scml2在诊断胃肠胰神经内分泌肿瘤中的应用 |
CN108085392A (zh) * | 2018-01-09 | 2018-05-29 | 山大生殖研发中心有限公司 | 上皮性卵巢癌的生物标志物及其用途 |
CN110241198A (zh) * | 2019-05-30 | 2019-09-17 | 成都吉诺迈尔生物科技有限公司 | 一种表征hHRD同源重组缺陷的基因组重组指纹及其鉴定方法 |
CN112229999A (zh) * | 2020-09-01 | 2021-01-15 | 浙江省肿瘤医院 | 一种卵巢癌的预后诊断标志物Claudin21及其应用 |
CN112229999B (zh) * | 2020-09-01 | 2022-04-22 | 浙江省肿瘤医院 | 一种卵巢癌的预后诊断标志物Claudin21及其应用 |
CN113684277A (zh) * | 2021-09-06 | 2021-11-23 | 南方医科大学南方医院 | 一种基于基因组拷贝数变异的生物标志物预测卵巢癌同源重组缺陷的方法及应用 |
CN113684277B (zh) * | 2021-09-06 | 2022-05-17 | 南方医科大学南方医院 | 一种基于基因组拷贝数变异的生物标志物预测卵巢癌同源重组缺陷的方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
EP1644522A2 (en) | 2006-04-12 |
WO2005005661A2 (en) | 2005-01-20 |
MXPA05014220A (es) | 2006-03-09 |
BRPI0412110A (pt) | 2006-11-21 |
WO2005005661A3 (en) | 2005-07-14 |
AU2004256182A1 (en) | 2005-01-20 |
JP2007526749A (ja) | 2007-09-20 |
CA2531091A1 (en) | 2005-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070198198A1 (en) | Methods and apparatuses for diagnosing AML and MDS | |
EP2504451B1 (en) | Methods to predict clinical outcome of cancer | |
US20030224411A1 (en) | Genes that are up- or down-regulated during differentiation of human embryonic stem cells | |
US20090203588A1 (en) | Outcome prediction and risk classification in childhood leukemia | |
US20040018513A1 (en) | Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling | |
US20110230372A1 (en) | Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia | |
US20050208496A1 (en) | Methods of testing for bronchial asthma or chronic obstructive pulmonary disease | |
US20050095607A1 (en) | Breast cancer signatures | |
EP1470247A2 (en) | Novel genetic markers for leukemias | |
US20060240441A1 (en) | Gene expression profiles and methods of use | |
KR20100095564A (ko) | 항-cd40 항체를 사용한 치료에 대한 b-세포 림프종의 반응성 평가를 위한 방법 및 조성물 | |
CN1845999A (zh) | 在卵巢癌中作为预后和治疗靶标而被调控的基因 | |
KR20140006898A (ko) | 결장암 유전자 발현 시그니처 및 이용 방법 | |
CN1890381A (zh) | 诊断乳腺癌的方法 | |
US20090118132A1 (en) | Classification of Acute Myeloid Leukemia | |
KR20090078365A (ko) | 혈액 백혈구 마이크로어레이 분석을 통한 전이성 흑색종의 진단 및 면역억제 지표의 모니터링 | |
CN101180407A (zh) | 白血病疾病基因和其用途 | |
KR20160117606A (ko) | 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험 | |
US10106855B2 (en) | Genetic assay to determine prognosis in Polycythemia Vera patients | |
AU2004210986A1 (en) | Methods for monitoring drug activities in vivo | |
US20070134690A1 (en) | Diagnosis of systemic onset juvenile idiopathic arthritis through blood leukocyte microarray analysis | |
US20050164196A1 (en) | Methods to predict patient responsiveness to tyrosine kinase inhibitors | |
CN1908189A (zh) | 体外辅助鉴定肠型胃癌及其分化程度的方法与专用试剂盒 | |
WO2010065926A2 (en) | Methods for screening, predicting and monitoring prostate cancer | |
CN1711361A (zh) | 预测药物治疗副效应水肿的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |